secwatch / observer
8-K filed September 9, 2021, 7:59 PM ET ticker LXRX CIK 0001062822
leadership confidence high sentiment neutral materiality 0.40

Lexicon appoints Jeffrey L. Wade as President, effective Oct 1, 2021; salary increased to $505k

LEXICON PHARMACEUTICALS, INC.

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Jeffrey L. Wade

President
LXRX · LEXICON PHARMACEUTICALS, INC.
Effective
2021-10-01
Filed
September 9, 2021, 7:59 PM ET
On September 3, 2021, in preparation for the potential commercial launch of sotagliflozin, if approved, and management of future growth of our company, our board of directors appointed Jeffrey L. Wade as president, effective October 1, 2021, continuing to report to Lonnel Coats, who remains our chief executive officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Jeffrey L. Wade was appointed as President at LEXICON PHARMACEUTICALS, INC..

Action
appointed
Role
President
Exact text from the filing
On September 3, 2021, in preparation for the potential commercial launch of sotagliflozin, if approved, and management of future growth of our company, our board of directors appointed Jeffrey L. Wade as president, effective October 1, 2021, continuing to report to Lonnel Coats, who remains our chief executive officer.
View on SEC.gov

LEXICON PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR
accession 0001062822-21-000055
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.